Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Journal of Neurochemistry
|
September 10, 2005
Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function
Magali Periquet, Olga Corti, Sandrine Jacquier, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
March 23, 2007
Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo
Magali Periquet, Tudor Fulga, Liisa Myllykangas, et al.
Clinical Pharmacology in Drug Development
|
September 14, 2023
Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000-L Scale in Participants with Pompe Disease: A Phase 3/4 Open-Label Study
Xavier Nicolas, Fabrice Hurbin, Magali Periquet, et al.
The Journal of Clinical Investigation
|
October 27, 2009
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation
Li Chen, Magali Periquet, Xu Wang, et al.
Molecular Genetics and Metabolism Reports
|
July 22, 2024
Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials
Tahseen Mozaffar, Lionel Riou França, Jérôme Msihid, et al.
Journal of Neuromuscular Diseases
|
December 31, 2023
Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa
Matthias Boentert, Emmanuelle Salort Campana, Shahram Attarian, et al.
Journal of Neuromuscular Diseases
|
May 21, 2025
Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease
Kenneth I Berger, Cristina Ivanescu, Jérôme Msihid, et al.
Orphanet Journal of Rare Diseases
|
December 7, 2023
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
Priya S Kishnani, David Kronn, Shugo Suwazono, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 31, 2003
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism
Sergei N Illarioshkin, Magali Periquet, Nina Rawal, et al.
Journal of Neurology
|
June 19, 2024
Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Journal of Neurochemistry
|
September 10, 2005
Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function
Magali Periquet, Olga Corti, Sandrine Jacquier, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
March 23, 2007
Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo
Magali Periquet, Tudor Fulga, Liisa Myllykangas, et al.
Clinical Pharmacology in Drug Development
|
September 14, 2023
Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000-L Scale in Participants with Pompe Disease: A Phase 3/4 Open-Label Study
Xavier Nicolas, Fabrice Hurbin, Magali Periquet, et al.
The Journal of Clinical Investigation
|
October 27, 2009
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation
Li Chen, Magali Periquet, Xu Wang, et al.
Molecular Genetics and Metabolism Reports
|
July 22, 2024
Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials
Tahseen Mozaffar, Lionel Riou França, Jérôme Msihid, et al.
Journal of Neuromuscular Diseases
|
December 31, 2023
Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa
Matthias Boentert, Emmanuelle Salort Campana, Shahram Attarian, et al.
Journal of Neuromuscular Diseases
|
May 21, 2025
Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease
Kenneth I Berger, Cristina Ivanescu, Jérôme Msihid, et al.
Orphanet Journal of Rare Diseases
|
December 7, 2023
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
Priya S Kishnani, David Kronn, Shugo Suwazono, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 31, 2003
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism
Sergei N Illarioshkin, Magali Periquet, Nina Rawal, et al.
Journal of Neurology
|
June 19, 2024
Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Page
of 2